UB Paderborn / Katalog / Suche / in CDI

Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review

Lipids in health and disease, 2017-08, Vol.16 (1), p.149-149, Article 149

2017

Link zum Volltext

Verfügbarkeit prüfen

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model1

Journal of lipid research, 2020-03, Vol.61 (3), p.272-274

Hurt-Camejo, Eva

2020

Link zum Volltext

Verfügbarkeit prüfen

An oral antisense oligonucleotide for PCSK9 inhibition

Science translational medicine, 2021-05, Vol.13 (593)

2021

Link zum Volltext

Verfügbarkeit prüfen

Does statins promote vascular calcification in chronic kidney disease?

European journal of clinical investigation, 2017-02, Vol.47 (2), p.137-148

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]

Journal of lipid research, 2019-09, Vol.60 (9), p.1610-1621

2019

Link zum Volltext

Verfügbarkeit prüfen

Lipids around the Clock: Focus on Circadian Rhythms and Lipid Metabolism

Biology, 2015-02, Vol.4 (1), p.104-132

2015

Link zum Volltext

Verfügbarkeit prüfen

Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)

Journal of lipid research, 2021-01, Vol.62, p.100065, Article 100065

2021

Link zum Volltext

Verfügbarkeit prüfen

ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker

Journal of cardiovascular development and disease, 2018-07, Vol.5 (3), p.36

2018

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease

Frontiers in pharmacology, 2022-09, Vol.13, p.988561-988561

2022

Link zum Volltext

Verfügbarkeit prüfen

Macrophages, extracellular matrix, and lipoproteins in arterial cholesterol balance

Journal of lipid research, 2014-01, Vol.55 (1), p.1-3

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 13307: An Oral Antisense Oligonucleotide for PCSK9 Inhibition in Humans

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A13307-A13307

2020

Link zum Volltext

Verfügbarkeit prüfen

Endothelial Lipase Mediates HDL Levels in Normal and Hyperlipidemic Rabbits

Journal of Atherosclerosis and Thrombosis, 2012, Vol.19(3), pp.213-226

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease

ACS medicinal chemistry letters, 2016-10, Vol.7 (10), p.884-889

2016

Link zum Volltext

Verfügbarkeit prüfen

Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis

Genome biology, 2007-01, Vol.8 (9), p.R200-R200

2007

Link zum Volltext

Verfügbarkeit prüfen

Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2 -IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease

Journal of the American College of Cardiology, 2014-03, Vol.63 (9), p.942-943

2014

Link zum Volltext

Verfügbarkeit prüfen

Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers

Frontiers in pharmacology, 2021-08, Vol.12, p.681455-681455

2021

Link zum Volltext

Verfügbarkeit prüfen

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model

Journal of lipid research, 2020-03, Vol.61 (3), p.272-274

Hurt-Camejo, Eva

2020

Link zum Volltext

Verfügbarkeit prüfen

Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice

Vascular pharmacology, 2014-05, Vol.61 (2), p.49-55

2014

Link zum Volltext

Verfügbarkeit prüfen

High Plasma Phospholipase A 2 Activity, Inflammation Markers, and LDL Alterations in Obesity With or Without Type 2 Diabetes

Obesity (Silver Spring, Md.), 2012-09, Vol.18 (10), p.2023-2029

2012

Link zum Volltext

Verfügbarkeit prüfen

Suppression of abdominal aortic aneurysm formation by AR-R17779, an agonist for the α7 nicotinic acetylcholine receptor

Atherosclerosis, 2016-01, Vol.244, p.113-120

2016

Link zum Volltext

Verfügbarkeit prüfen

Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis

Molecular therapy. Methods & clinical development, 2018-09, Vol.10, p.17-28

2018

Link zum Volltext

Verfügbarkeit prüfen

Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase

Journal of lipid research, 2010-07, Vol.51 (7), p.1801-1809

2010

Link zum Volltext

Verfügbarkeit prüfen

Phospholipase A2 enzymes and the risk of atherosclerosis

European heart journal, 2012-12, Vol.33 (23), p.2899-2909

2012

Link zum Volltext

Verfügbarkeit prüfen

Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis

Biochimica et biophysica acta. Molecular and cell biology of lipids, 2006-11, Vol.1761 (11), p.1301-1308

2006

Link zum Volltext

Verfügbarkeit prüfen

Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and Glycosaminoglycans

The Journal of biological chemistry, 1999-09, Vol.274 (36), p.25913-25920

1999

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model1

An oral antisense oligonucleotide for PCSK9 inhibition

Does statins promote vascular calcification in chronic kidney disease?

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]

Lipids around the Clock: Focus on Circadian Rhythms and Lipid Metabolism

Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)

ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease

Macrophages, extracellular matrix, and lipoproteins in arterial cholesterol balance

Abstract 13307: An Oral Antisense Oligonucleotide for PCSK9 Inhibition in Humans

Endothelial Lipase Mediates HDL Levels in Normal and Hyperlipidemic Rabbits

Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease

Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis

Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2 -IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease

Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers

ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model

Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice

High Plasma Phospholipase A 2 Activity, Inflammation Markers, and LDL Alterations in Obesity With or Without Type 2 Diabetes

Suppression of abdominal aortic aneurysm formation by AR-R17779, an agonist for the α7 nicotinic acetylcholine receptor

Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis

Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase

Phospholipase A2 enzymes and the risk of atherosclerosis

Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis

Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and Glycosaminoglycans

Suchergebnisse filtern